(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

INIBIDORES TERAPÊUTICOS DE TIROSINA CINASE E SEUS USOS NO TRATAMENTO DE ESCLEROSE MÚLTIPLA RECIDIVANTE (RMS)

Em ExigênciaInvention PatentPCT · US2021013883

Application data

Number

112022014058

Type

Invention Patent

Filing

01/19/2021

Publication

09/13/2022

PCT

US2021013883

Progress at the INPI

Technical opinion to answer
  1. Filing01/19/21
  2. Publication09/13/22
  3. Examination
  4. Allowance
  5. Grant
  6. In force

The INPI issued a technical opinion on patentability. The applicant must respond for examination to continue.

Leave your contact and we will alert you

We track INPI publications and let you know as soon as this case moves.

We use your details only for this alert.

Latest action published by the INPI: 08/18/2026. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

G. C. (pessoa física)

US

PRINCIPIA BIOPHARMA INC.

US

See this company's full portfolio

Inventors

E. W. (pessoa física)

US

M. C. (pessoa física)

US

T. T. (pessoa física)

US

Technical data

Priority claims

US

62/963,238 · 01/20/2020

US

62/970,502 · 02/05/2020

US

63/013,895 · 04/22/2020

Abstract

INIBIDORES TERAPÊUTICOS DE TIROSINA CINASE PARA ESCLEROSE MÚLTIPLA RECIDIVANTE (RMS). A presente invenção refere-se ao campo de inibidores de tirosina cinase terapêuticos, em particular, inibidores de tirosina cinase de Bruton ("BTK") para tratamento de indivíduos com esclerose múltipla recidivante.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Parecer de pré-exame

#6.23

08/18/2026

RPI 2902

Alteração de sede deferida

#25.7

12/23/2025

RPI 2868

Transferência deferida

#25.1

12/09/2025

RPI 2866

Notificação de entrada na fase nacional - PCT

#1.3

09/13/2022

RPI 2697

Alteração de dados cadastrais

#1.1

07/26/2022

RPI 2690

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.